BR112013028892A2 - proteína de ligação à biotina modificada, proteínas de fusão da mesma e aplicações - Google Patents

proteína de ligação à biotina modificada, proteínas de fusão da mesma e aplicações

Info

Publication number
BR112013028892A2
BR112013028892A2 BR112013028892A BR112013028892A BR112013028892A2 BR 112013028892 A2 BR112013028892 A2 BR 112013028892A2 BR 112013028892 A BR112013028892 A BR 112013028892A BR 112013028892 A BR112013028892 A BR 112013028892A BR 112013028892 A2 BR112013028892 A2 BR 112013028892A2
Authority
BR
Brazil
Prior art keywords
applications
biotin binding
protein
modified biotin
fusion protein
Prior art date
Application number
BR112013028892A
Other languages
English (en)
Other versions
BR112013028892B1 (pt
Inventor
Zhang Fan
Malley Richard
Lu Yingjie
Original Assignee
Children's Medical Center Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Children's Medical Center Corp filed Critical Children's Medical Center Corp
Publication of BR112013028892A2 publication Critical patent/BR112013028892A2/pt
Publication of BR112013028892B1 publication Critical patent/BR112013028892B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0275—Salmonella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/555—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells
    • A61K47/557—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells the modifying agent being biotin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6093—Synthetic polymers, e.g. polyethyleneglycol [PEG], Polymers or copolymers of (D) glutamate and (D) lysine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/625—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier binding through the biotin-streptavidin system or similar
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
    • A61K2039/645—Dendrimers; Multiple antigen peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112013028892-2A 2011-05-11 2012-05-11 Proteína de ligação à biotina modificada, proteínas de fusão da mesma e aplicações BR112013028892B1 (pt)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201161484934P 2011-05-11 2011-05-11
US61/484,934 2011-05-11
US201261608168P 2012-03-08 2012-03-08
US61/608,168 2012-03-08
US201261609974P 2012-03-13 2012-03-13
US61/609,974 2012-03-13
PCT/US2012/037541 WO2012155053A1 (en) 2011-05-11 2012-05-11 Modified biotin-binding protein, fusion proteins thereof and applications

Publications (2)

Publication Number Publication Date
BR112013028892A2 true BR112013028892A2 (pt) 2017-01-31
BR112013028892B1 BR112013028892B1 (pt) 2021-06-15

Family

ID=47139675

Family Applications (2)

Application Number Title Priority Date Filing Date
BR112013028892-2A BR112013028892B1 (pt) 2011-05-11 2012-05-11 Proteína de ligação à biotina modificada, proteínas de fusão da mesma e aplicações
BR112013028887-6A BR112013028887B1 (pt) 2011-05-11 2012-05-11 Composição imunogênica apresentando múltiplos antígenos, e métodos e usos dos mesmos

Family Applications After (1)

Application Number Title Priority Date Filing Date
BR112013028887-6A BR112013028887B1 (pt) 2011-05-11 2012-05-11 Composição imunogênica apresentando múltiplos antígenos, e métodos e usos dos mesmos

Country Status (13)

Country Link
US (7) US10766932B2 (pt)
EP (4) EP2706991B1 (pt)
JP (7) JP6366501B2 (pt)
KR (4) KR102494245B1 (pt)
CN (4) CN108840912B (pt)
AU (2) AU2012253359B2 (pt)
BR (2) BR112013028892B1 (pt)
CA (2) CA2835630A1 (pt)
ES (2) ES2864765T3 (pt)
MX (2) MX2013013112A (pt)
RU (2) RU2619176C2 (pt)
WO (2) WO2012155007A1 (pt)
ZA (2) ZA201308461B (pt)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ521396A (en) * 2000-02-28 2004-06-25 Chiron S Fusion proteins comprising two or more Neisseria polypeptides
US9125863B2 (en) * 2008-05-22 2015-09-08 Children's Medical Center Corporation Synergistic immunogenic fusion protein-polysaccharide conjugate
RU2619176C2 (ru) * 2011-05-11 2017-05-12 Чилдрен'С Медикал Сентер Корпорейшн Иммуногенная композиция презентации множественных антигенов, относящиеся к ней способы и применения
WO2012164480A1 (en) * 2011-05-30 2012-12-06 National Institute Of Immunology A vaccine composition capable of inducing memory antibody response from single point immunization
WO2013043643A1 (en) * 2011-09-21 2013-03-28 St. Jude Children's Research Hospital Live, attenuated streptococcus pneumoniae strain and vaccine for protection against pneumococcal disease
WO2014059144A1 (en) 2012-10-10 2014-04-17 Arizona Board Of Regents Acting For And On Behalf Of Arizona State University Systems and devices for molecule sensing and method of manufacturing thereof
ES2959258T3 (es) * 2013-02-07 2024-02-22 Childrens Medical Center Antígenos proteicos que proporcionan protección contra la colonización y/o la enfermedad neumocócicas
US9981997B2 (en) 2013-10-31 2018-05-29 Arizona Board Of Regents On Behalf Of Arizona State University Chemical reagents for attaching affinity molecules on surfaces
US10080790B2 (en) 2014-09-19 2018-09-25 The Regents Of The University Of Michigan Staphylococcus aureus materials and methods
CN104548101B (zh) * 2015-01-31 2017-02-22 广东海大畜牧兽医研究院有限公司 一种诱导哺乳动物乳腺黏膜产生IgA的免疫增强剂及其制备方法和应用
CN105646681B (zh) * 2016-01-21 2021-07-16 浙江海隆生物科技有限公司 一种奶牛金黄色葡萄球菌α-溶血素亚单位疫苗的制备方法及应用
EP3443001A4 (en) 2016-04-11 2020-04-29 Obsidian Therapeutics, Inc. REGULATED BIOCIRCUIT SYSTEMS
US20190119332A1 (en) * 2016-05-04 2019-04-25 The Children's Medical Center Corporation Methods to purify avidin-like proteins and fusion proteins thereof
US10751398B2 (en) * 2016-10-07 2020-08-25 Loyola University Chicago Inflammasome activators and methods of use to treat tumors
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US11951165B2 (en) 2016-12-30 2024-04-09 Vaxcyte, Inc. Conjugated vaccine carrier proteins
JP7186166B2 (ja) 2016-12-30 2022-12-08 バックスサイト・インコーポレイテッド 非天然アミノ酸とのポリペプチド抗原接合体
US20180161433A1 (en) * 2017-03-22 2018-06-14 Timothy Andrew Erickson Size tunable microbial mimetics for immunotherapy of thyroid carcinomas and solid tumors
US11305001B2 (en) 2017-03-28 2022-04-19 The Children's Medical Center Corporation Multiple antigen presenting system (MAPS)-based Staphylococcus aureus vaccine, immunogenic composition, and uses thereof
US20200121777A1 (en) * 2017-05-22 2020-04-23 The Children's Medical Center Corporation Combined vaccine against mycobacterium tuberculosis
US10729763B2 (en) 2017-06-10 2020-08-04 Inventprise, Llc Mixtures of polysaccharide-protein pegylated compounds
JP7132954B2 (ja) 2017-06-10 2022-09-07 インベントプライズ リミテッド ライアビリティ カンパニー 改善された免疫原性及び結合活性を提供する２価又は多価コンジュゲート多糖を含む多価コンジュゲートワクチン
MX2019015524A (es) 2017-06-23 2020-09-10 Univ Maryland Composiciones inmunogenicas.
EP3654956A4 (en) * 2017-07-19 2021-04-28 Children's Medical Center Corporation COMPOSITIONS AND METHODS OF TREATMENT OF DISEASES ASSOCIATED WITH AN IMPRINTING DEFECTIVE
CN111479558A (zh) * 2017-10-13 2020-07-31 纽约州立大学研究基金会 用于共生疾病进展的综合疫苗设计
CN108339115B (zh) * 2018-05-11 2020-07-10 武汉博沃生物科技有限公司 使用重组载体蛋白的肺炎球菌联合疫苗及其制备方法
EP3806888B1 (en) 2018-06-12 2024-01-31 Obsidian Therapeutics, Inc. Pde5 derived regulatory constructs and methods of use in immunotherapy
CN112969474A (zh) * 2018-09-12 2021-06-15 艾芬尼维克斯公司 多价肺炎球菌疫苗
US20200087361A1 (en) * 2018-09-12 2020-03-19 The Children's Medical Center Corporation Pneumococcal fusion protein vaccines
US20210386788A1 (en) 2018-10-24 2021-12-16 Obsidian Therapeutics, Inc. Er tunable protein regulation
CN109400704B (zh) * 2018-11-14 2020-07-21 珠海泰诺麦博生物技术有限公司 一种抗金黄色葡萄球菌α-溶血素的抗体及其应用
CA3132840A1 (en) 2019-03-08 2020-09-17 Obsidian Therapeutics, Inc. Human carbonic anhydrase 2 compositions and methods for tunable regulation
WO2020223240A1 (en) * 2019-04-29 2020-11-05 The Broad Institute, Inc. Affinity-based multiplexing for live-cell monitoring of complex cell populations
MX2021015097A (es) 2019-06-12 2022-04-01 Obsidian Therapeutics Inc Composiciones de ca2 y metodos para regulación ajustable.
EP3983537A1 (en) 2019-06-12 2022-04-20 Obsidian Therapeutics, Inc. Ca2 compositions and methods for tunable regulation
CN111518822B (zh) * 2019-07-02 2022-08-09 江南大学 一种硫酸软骨素abc裂解酶突变体及其分泌表达的方法
JP2021029171A (ja) * 2019-08-23 2021-03-01 国立大学法人東京農工大学 ブレビバチルス菌を用いた表層提示法
WO2021046451A1 (en) 2019-09-06 2021-03-11 Obsidian Therapeutics, Inc. Compositions and methods for dhfr tunable protein regulation
US20220401542A1 (en) * 2019-11-05 2022-12-22 Beth Israel Deaconess Medical Center, Inc. Mycobacterial compositions and biomarkers for use in treatment and monitoring of therapeutic responsiveness
US20230340402A1 (en) * 2019-12-27 2023-10-26 Amolifescience Co., Ltd. Cell culture substrate and manufacturing method thereof
US20230056844A1 (en) * 2019-12-27 2023-02-23 Amolifescience Co., Ltd. Cell culture substrate and manufacturing method therefor
CN116113644A (zh) * 2020-09-14 2023-05-12 神州细胞工程有限公司 通过糖-冠状病毒rbd抗原缀合物提高免疫原性的方法
WO2022216734A1 (en) * 2021-04-06 2022-10-13 The Board Of Trustees Of The University Of Illinois Multivalent cholera multiepitope fusion antigen (mefa) and methods of use
US20230233667A1 (en) 2021-09-08 2023-07-27 Affinivax, Inc. Coronavirus vaccine
CA3231684A1 (en) * 2021-09-09 2023-03-16 Affinivax, Inc. Multivalent pneumococcal vaccines
WO2023069278A1 (en) * 2021-10-20 2023-04-27 Fina Biosolutions, Llc Chemical reagents for the activation of polysaccharides in the preparation of conjugate vaccines
IL312219A (en) 2021-11-02 2024-06-01 Arvada Therapeutics Inc DSG2 preparations and methods
WO2023102359A1 (en) * 2021-12-02 2023-06-08 The Children's Medical Center Corporation A maps vaccine targeting salmonella enterica serovars
WO2023192997A2 (en) * 2022-03-31 2023-10-05 The Children's Medical Center Corporation Immunogenic compositions for b-cell recall response to a polysaccharide antigen
WO2024081906A1 (en) * 2022-10-14 2024-04-18 The Children's Medical Center Corporation A maps vaccine targeting group b streptococcus (gbs)
WO2024081871A1 (en) * 2022-10-14 2024-04-18 The Children's Medical Center Corporation Shigella multiple antigen presenting immunogenic composition and fusion proteins thereof
US20240181028A1 (en) 2022-11-22 2024-06-06 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
CN115819624B (zh) * 2022-12-16 2023-12-15 深圳华腾生物医药科技有限公司 一种重组融合蛋白及其制备方法和应用

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US244420A (en) 1881-07-19 Stove pipe threadeb and beader
US3887699A (en) 1969-03-24 1975-06-03 Seymour Yolles Biodegradable polymeric article for dispensing drugs
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
PH19942A (en) 1980-11-18 1986-08-14 Sintex Inc Microencapsulation of water soluble polypeptides
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4673641A (en) 1982-12-16 1987-06-16 Molecular Genetics Research And Development Limited Partnership Co-aggregate purification of proteins
US4745051A (en) 1983-05-27 1988-05-17 The Texas A&M University System Method for producing a recombinant baculovirus expression vector
DE3413608A1 (de) 1984-04-11 1985-10-24 Hoechst Ag, 6230 Frankfurt Implantierbare zubereitungen von regulatorischen peptiden mit gesteuerter freisetzung und verfahren zu ihrer herstellung
US4879236A (en) 1984-05-16 1989-11-07 The Texas A&M University System Method for producing a recombinant baculovirus expression vector
US5030719A (en) 1986-08-28 1991-07-09 Teijin Limited Cytotoxic antibody conjugates and a process for preparation thereof
NZ224422A (en) 1987-05-05 1990-11-27 Molecular Eng Ass Composition adapted for intranasal immunisation against viral infection comprising a glycoprotein complexed with a lipid
US5229490A (en) 1987-05-06 1993-07-20 The Rockefeller University Multiple antigen peptide system
US5179007A (en) 1989-07-07 1993-01-12 The Texas A & M University System Method and vector for the purification of foreign proteins
FR2664905B1 (fr) 1990-07-18 1994-08-12 Agronomique Inst Nat Rech Baculovirus modifie, son procede d'obtention, et vecteurs d'expression obtenus a partir dudit baculovirus.
US5516657A (en) 1992-05-11 1996-05-14 Cambridge Biotech Corporation Baculovirus vectors for expression of secretory and membrane-bound proteins
US5390111A (en) 1993-11-12 1995-02-14 General Electric Company Method and system for processing cone beam data for reconstructing free of boundary-induced artifacts a three dimensional computerized tomography image
AU1377395A (en) 1993-12-23 1995-07-10 University Technologies International Inc. Methods of expressing proteins in insect cells and methods of killing insects
IL112372A (en) 1994-02-07 2001-08-26 Res Dev Foundation Non-viral vector for the delivery of genetic information to cells
AU712981B2 (en) 1995-03-22 1999-11-18 Henry M. Jackson Foundation For The Advancement Of Military Medicine Producing immunogenic constructs using soluble carbohydrates activated via organic cyanylating reagents
SE506793C2 (sv) 1996-09-19 1998-02-09 Atlas Copco Rocktech Ab Kopplingsstycke för användning vid samtidig jord- och/eller bergborrning med en övre rotationsslaganordning och en undre slaganordning
EP1770164B1 (en) 1996-10-31 2010-09-01 Human Genome Sciences, Inc. Streptococcus pneumoniae antigens and vaccines
CA2288267A1 (en) 1997-04-24 1998-10-29 Henry M. Jackson Foundation For The Advancement Of Military Medicine Coupling of unmodified proteins to haloacyl or dihaloacyl derivatized polysaccharides for the preparation of protein-polysaccharide vaccines
US7060458B1 (en) * 1997-08-14 2006-06-13 Wyeth Nucleic acid and amino acid sequences relating to Staphylococcus epidermidis for diagnostics and therapeutics
AU9310298A (en) 1997-09-09 1999-03-29 Trustees Of Columbia University In The City Of New York, The T-independent conjugate-vaccines
SE9900496D0 (sv) 1999-02-12 1999-02-12 Pharmatrix Ab Vaccine formulation
US6398774B1 (en) 1999-09-29 2002-06-04 Heska Corporation Intranasal delivery system
US8246945B2 (en) 2000-04-06 2012-08-21 University Of Arkansas Methods and reagents for decreasing clinical reaction to allergy
US6919187B2 (en) 2000-04-21 2005-07-19 Corixa Corporation Compounds and methods for treatment and diagnosis of chlamydial infection
US20020051794A1 (en) 2000-08-09 2002-05-02 Alk-Abello A/S Novel parenteral vaccine formulations and uses thereof
GB0107658D0 (en) 2001-03-27 2001-05-16 Chiron Spa Streptococcus pneumoniae
AU2003239744B2 (en) * 2002-05-14 2008-07-03 Novartis Vaccines And Diagnostics S.R.L. Mucosal combination vaccines for bacterial meningitis
US20060251675A1 (en) * 2003-03-17 2006-11-09 Michael Hagen Mutant cholera holotoxin as an adjuvant and an antigen carrier protein
CA2522238A1 (en) 2003-04-15 2004-10-28 Intercell Ag S. pneumoniae antigens
US20050002948A1 (en) 2003-05-07 2005-01-06 Ryall Robert P. Method of enhanced immunogenicity to meningococcal vaccination
EP2481422A3 (en) 2003-09-03 2013-04-03 Dendritherapeutics, Inc. Multiplex vaccines
US7611712B2 (en) 2003-10-23 2009-11-03 Nelson M. Karp Immunogenic compositions capable of eliciting Th1 immune responses comprising an HIV-1 MA myristate binding site polypeptide
MXPA06007144A (es) 2003-12-24 2007-01-31 Cerus Corp Moleculas de acido nucleico recombinante que codifican proteinas de fusion que comprenden polipeptidos de senal secretoria bacterial y de antigenos, casetes de expresion y bacterias, y metodos para usar las mismas.
EP1740604A2 (en) 2004-04-27 2007-01-10 Intercell AG Td antigens
GB0410220D0 (en) * 2004-05-07 2004-06-09 Kirkham Lea Ann Mutant pneumolysin proteins
ATE512230T1 (de) 2004-08-18 2011-06-15 Univ Alberta Proteinherstellungsverfahren unter nutzung von yebf
FI20041396A0 (fi) * 2004-10-29 2004-10-29 Vesa Pekka Hytoenen Uudet mikrobiavidiinit
WO2006050571A1 (en) 2004-11-11 2006-05-18 Queensland University Of Technology Chlamydia antigens and uses thereof
GB0428394D0 (en) 2004-12-24 2005-02-02 Chiron Srl Saccharide conjugate vaccines
CA2597489A1 (en) 2005-02-11 2006-08-17 Ace Biosciences A/S Surface-located streptococcus pneumoniae polypeptides
US20090148894A1 (en) 2005-08-15 2009-06-11 Broedel Sheldon E Methods for optimizing the secretion of protein in prokaryotes
ES2443529T3 (es) * 2005-09-01 2014-02-19 Novartis Vaccines And Diagnostics Gmbh Vacunación múltiple incluyendo meningococo del serogrupo C
AU2006321888A1 (en) * 2005-12-08 2007-06-14 University Of Louisville Research Foundation, Inc. Immunostimulatory compositions and methods
WO2007081583A2 (en) * 2006-01-04 2007-07-19 Children's Medical Center Corporation Anti-pneumococcal preparations and methods of use
US7943133B2 (en) 2006-02-02 2011-05-17 Boston Biocom Llc Mesothelin antibody protein fusions and methods of use
US20080032340A1 (en) 2006-06-09 2008-02-07 University Of Arizona Peptide motifs for binding avidin or neutravidin
WO2007149982A2 (en) 2006-06-22 2007-12-27 The Brigham And Women's Hospital, Inc. Diagnosis of autoimmune disease
WO2007150020A1 (en) * 2006-06-23 2007-12-27 Simon Paul M Targeted immune conjugates
US7452985B2 (en) 2006-08-17 2008-11-18 Visgeneer, Inc. Human Ron-related gene variant associated with cancers
EP2104512A2 (en) 2006-12-21 2009-09-30 Emergent Product Development UK Limited Streptococcus proteins, and their use in vaccination
CN100579152C (zh) 2007-01-29 2010-01-06 华为技术有限公司 一种播放集团彩铃的方法、系统及装置
US7618799B2 (en) 2007-01-31 2009-11-17 Dow Global Technologies Inc Bacterial leader sequences for increased expression
WO2009023300A2 (en) 2007-04-13 2009-02-19 The Board Of Regents Of The University Of Oklahoma Mutants of cholesterol-dependent cytolysins and uses thereof
CN101784282B (zh) 2007-06-26 2015-07-08 葛兰素史密丝克莱恩生物有限公司 包含肺炎链球菌荚膜多糖缀合物的疫苗
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
WO2009020553A2 (en) 2007-08-03 2009-02-12 President And Fellows Of Harvard College Chlamydia antigens
WO2009021548A1 (en) * 2007-08-10 2009-02-19 Wacker Chemie Ag Expression of full length igg and secretion into the culture medium of prokaryotic cells
EP2666784B1 (en) 2007-08-31 2017-04-05 University Of Chicago Methods and compositions related to immunizing against staphylococcal lung diseases and conditions
CA2748149C (en) 2008-12-24 2018-03-06 Netherlands Vaccine Institute Modified steptococcus pneumonia pneumolysin (ply) polypeptides
EP2208787A1 (en) * 2009-01-19 2010-07-21 Université de Liège A recombinant alpha-hemolysin polypeptide of Staphylococcus aureus, having a deletion in the stem domain and heterologous sequences inserted
BRPI1013780B8 (pt) 2009-04-14 2022-10-04 Novartis Ag Composição imunogênica útil para imunização contra staphylococcus aureus, seu método de preparação e composição farmacêutica
US8828953B2 (en) * 2009-04-20 2014-09-09 NaZura BioHealth, Inc. Chemosensory receptor ligand-based therapies
CN107126557A (zh) * 2009-06-29 2017-09-05 健诺西生物科学公司 抗肺炎链球菌的疫苗和组合物
CN101797381B (zh) 2010-01-29 2012-05-23 中国人民解放军第三军医大学 乙肝病毒抗原与路易斯寡糖的复合物及其制备方法和应用
EP2563396A2 (en) * 2010-04-30 2013-03-06 Augmenta Biologicals LLC Delivery proteins
RU2619176C2 (ru) 2011-05-11 2017-05-12 Чилдрен'С Медикал Сентер Корпорейшн Иммуногенная композиция презентации множественных антигенов, относящиеся к ней способы и применения
WO2014018904A1 (en) 2012-07-26 2014-01-30 Genocea Biosciences, Inc. Fused antigen vaccines and compositions against streptococcus pneumoniae
ES2959258T3 (es) 2013-02-07 2024-02-22 Childrens Medical Center Antígenos proteicos que proporcionan protección contra la colonización y/o la enfermedad neumocócicas
US11305001B2 (en) 2017-03-28 2022-04-19 The Children's Medical Center Corporation Multiple antigen presenting system (MAPS)-based Staphylococcus aureus vaccine, immunogenic composition, and uses thereof
CN112969474A (zh) 2018-09-12 2021-06-15 艾芬尼维克斯公司 多价肺炎球菌疫苗

Also Published As

Publication number Publication date
CN108840912A (zh) 2018-11-20
KR20140053903A (ko) 2014-05-08
US10766932B2 (en) 2020-09-08
KR20210037018A (ko) 2021-04-05
JP6666389B2 (ja) 2020-03-13
RU2013154706A (ru) 2015-06-20
JP2014514363A (ja) 2014-06-19
EP2706991A4 (en) 2015-05-06
ZA201308465B (en) 2019-03-27
WO2012155053A1 (en) 2012-11-15
BR112013028892B1 (pt) 2021-06-15
JP2017193557A (ja) 2017-10-26
US20190119335A1 (en) 2019-04-25
EP2709603A1 (en) 2014-03-26
JP2018197237A (ja) 2018-12-13
RU2632651C2 (ru) 2017-10-06
US11560410B2 (en) 2023-01-24
JP6502420B2 (ja) 2019-04-17
WO2012155007A1 (en) 2012-11-15
CN103648489A (zh) 2014-03-19
US20140154286A1 (en) 2014-06-05
US20200407404A1 (en) 2020-12-31
RU2013154489A (ru) 2015-06-20
AU2012253327B2 (en) 2017-05-25
KR102234933B1 (ko) 2021-04-05
MX2013013112A (es) 2014-06-23
US20210332090A1 (en) 2021-10-28
US20240025952A1 (en) 2024-01-25
JP6152378B2 (ja) 2017-06-21
US11981708B2 (en) 2024-05-14
KR102494245B1 (ko) 2023-01-31
ZA201308461B (en) 2020-05-27
ES2864764T3 (es) 2021-10-14
JP2020079300A (ja) 2020-05-28
ES2864765T3 (es) 2021-10-14
KR20190104631A (ko) 2019-09-10
AU2012253359A1 (en) 2013-11-28
BR112013028887B1 (pt) 2020-10-06
AU2012253327A1 (en) 2013-11-28
EP2709603A4 (en) 2015-08-26
CN103732222A (zh) 2014-04-16
CA2835628C (en) 2023-01-03
JP2014517835A (ja) 2014-07-24
EP3881836A1 (en) 2021-09-22
EP2709603B1 (en) 2021-03-24
RU2619176C2 (ru) 2017-05-12
EP3912619A1 (en) 2021-11-24
AU2012253359B2 (en) 2017-06-08
US10017548B2 (en) 2018-07-10
JP2023162283A (ja) 2023-11-08
EP2706991B1 (en) 2021-03-24
US11976097B2 (en) 2024-05-07
CN108840912B (zh) 2023-07-04
US20160090404A1 (en) 2016-03-31
JP7336402B2 (ja) 2023-08-31
CA2835628A1 (en) 2012-11-15
CN108714212A (zh) 2018-10-30
KR102084509B1 (ko) 2020-03-05
EP2706991A1 (en) 2014-03-19
CN103732222B (zh) 2018-12-28
MX2013013111A (es) 2015-03-04
US20140154287A1 (en) 2014-06-05
CA2835630A1 (en) 2012-11-15
US10611805B2 (en) 2020-04-07
JP6366501B2 (ja) 2018-08-01
KR20140146993A (ko) 2014-12-29
JP2019104758A (ja) 2019-06-27
US9499593B2 (en) 2016-11-22

Similar Documents

Publication Publication Date Title
BR112013028892A2 (pt) proteína de ligação à biotina modificada, proteínas de fusão da mesma e aplicações
LTPA2019012I1 (lt) Plazmos kalikreiną surišantys baltymai
DK2768958T3 (da) Kationiske aminlipider og anvendelser deraf
DK2822575T3 (da) Manipulerede, muterede antistof-interferon-fusionsmolekyler
DK2850103T3 (da) ST2-antigenbindende proteiner
BR112014030278A2 (pt) anticorpo, e, composição.
BR112013014278A2 (pt) proteínas de ligação a tnf-a
DK2914291T3 (da) Anti-komplement-c1s-antistoffer og anvendelser deraf
BR112014009050A2 (pt) pirrolbenzodiazepinas e conjugados destas
DK2794654T3 (da) Anti-phf-tau-antistoffer og deres anvendelser
BR112014012137A2 (pt) anticorpos anti-fgfr2 e suas utilizações
DK3118221T3 (da) Proteiner
BR112015003838A2 (pt) formulações de anticorpo e proteína
CO6900146A2 (es) Imidazopiridazinas sustituidas con amino
DK2812356T3 (da) CDIM-bindende proteiner og anvendelser deraf
DK3431492T3 (da) Humane cd30-ligandantigen-bindende proteiner
DK3434775T3 (da) Protein med nukleaseaktivitet, fusionsproteiner og anvendelser deraf
DK3351255T3 (da) Modificerede anti-cd4-antistoffer
DK2721152T3 (da) Dimere bindingsproteiner baseret på modificerede ubiquitiner
BR112013030352A2 (pt) proteínas de ligação do receptor fc
BR112013013548A2 (pt) proteína de fusão anticancerígena
BRDI7004389S (pt) Configuração aplicada à recipiente
DK3173102T3 (da) FGFR-FC-fusionsprotein og anvendelse deraf
DK2598525T3 (da) Frataxin-mutanter
DK2704744T3 (da) Komplementfaktor-b-analoger og anvendelser deraf

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 11/05/2012, OBSERVADAS AS CONDICOES LEGAIS.